RT Journal Article
SR Electronic
T1 Improving Clinical Decision-Making in Radiotherapy: A Comparative Analysis of LQ and LQL Dose Models
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2025.03.05.25323402
DO 10.1101/2025.03.05.25323402
A1 Voyant, Cyril
A1 Julian, Daniel
A1 Muraro, Stéphane
A1 Bodez, Véronique
A1 Pinpin, Morgane
A1 Leschi, Delphine
A1 Oozeer, Rashid
A1 Guiddi, Wided
A1 Acquaviva, Marie-Aimée
A1 Prapant, Severine
A1 Gahbiche, Omar
A1 Bouaouina, Noureddine
YR 2025
UL http://medrxiv.org/content/early/2025/03/06/2025.03.05.25323402.abstract
AB Radiotherapy is an essential component of cancer treatment, requiring accurate dose planning to optimize tumor control while sparing healthy tissues. This study investigates advanced dose modeling approaches, focusing on the Linear Quadratic (LQ) and Linear Quadratic Linear (LQL) models, to refine the calculation of biologically effective doses (BED) and improve treatment personalization. Using tools such as LQL-equiv and other BED calculators, we integrated patient-specific data (e.g., fractionation schedules and organ-at-risk (OAR) constraints) to predict outcomes such as normal tissue complication probabilities (NTCP). Through a series of clinical case studies (including treatment interruptions, palliative boosts, and reirradiation scenarios), participant responses were analyzed using the Jaccard similarity index, revealing a significant lack of consensus in treatment planning decisions (mean agreement of 10%). This variability highlights a critical gap between the potential of advanced modeling and its consistent clinical application. While the LQ and LQL models offer promising tools for personalized radiotherapy, their interpretation and implementation remain highly variable. This study emphasizes the need for standardized guidelines, enhanced training programs, and decision-support systems to reduce inter-observer variability and ensure effective clinical adoption, ultimately improving patient care.HighlightsAdvanced dose modeling using LQ and LQL frameworks for precise radiotherapy planning.Accurate computation of BED and NTCP to optimize tumor control and minimize toxicity.Patient-specific optimization integrating fractionation schedules and OAR constraints.Clinical validation through case studies, revealing variability in treatment planning decisions.Call for standardized guidelines and training to bridge the gap between theory and practice.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes